A biologic analogue of C-type natriuretic peptide is showing promise as a therapy to improve bone growth in children with achondroplasia. An international phase 2 dose-finding and extension study, led by Melbourne clinical geneticist Professor Ravi Savarirayan, has found daily subcutaneous injections of vosoritide were well tolerated in the children. The study of 35 children ...
Bone growth promoter promises better therapy for achondroplasia
20 Jun 2019